The impact of micro troponin leak on long-term outcomes following elective percutaneous coronary intervention

Catheterization and Cardiovascular Interventions

Volumn 74, Issue 6, 2009, Pages 819-822

  Milani, Richard V ^a   Fitzgerald, Robert ^a   Milani, Jenna N ^a   Lavie, Carl J ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Outcomes; PCI; Troponin

Indexed keywords

TROPONIN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN; UP-REGULATION;

EID: 73249116247     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22160     Document Type: Article

References (20)

1. Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol 2004;57:1025-1026.
2. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-2653.
3. Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003;49:1331-1336.
4. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-1349.
5. Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J 2003;24:1314-1322.
6. Nageh T, Sherwood RA, Harris BM, Thomas MR. Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease. Heart 2005;91:1181-1185.
7. Nienhuis MB, Ottervanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F. Prognostic value of troponin after elective percutaneous coronary intervention: A meta-analysis. Catheter Cardiovasc Interv 2008;71:318-324.
8. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 2006;48:1765-1770.
9. Christenson RH, Duh SH, Apple FS, et al. Toward standardization of cardiac troponin I measurements. II. Assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. Clin Chem 2006;52:1685-1692.
10. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333-1341.
11. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002;40:662-668.
12. Jeremias A, Kleiman NS, Nassif D, et al. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: Results from the evaluation of drug eluting stents and ischemic events registry. Circulation 2008;118:632-638.
13. Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 substudy. Treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy-thrombolysis in myocardial infarction. Circulation 2002;106:202-207.
14. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-580.
15. Ray MJ, Walters DL, Bett JN, Cameron J, Wood P, Aroney CN. Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab. Int J Cardiol 2005;101:249-255.
16. Kiyak JH, Zerbino DD. Pathogenesis and morphogenesis of microcirculatory disorders in myocardial infarction. Clinical and ultrastructural examination. Pol J Pathol 1996;47:27-32.
17. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISARREACT 2 randomized trial. JAMA 2006;295:1531-1538.
18. Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: Focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 2000;85:50B-60B.
19. Nienhuis MB, Ottervanger JP, Miedema K, et al. Pre-treatment with clopidogrel and postprocedure troponin elevation after elective percutaneous coronary intervention. Thromb Haemost 2006;95:337-340.
20. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation 2005;111:2099-2106.